EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.

BMC Cancer · 2019 · PMC6534855 · PMID 31126258

Europe PMC DOI

hedged sentence

0.5850

closest p · 11.7× alpha

0.5850

boldest claim

The sentences

did not reach statistical significancep = 0.585not close (p > 0.1)

In contrast, in advanced HER2+ GC, the addition of pertuzumab to capecitabine/cisplatin/trastuzumab improved survival by 3.3 months, which did not reach statistical significance ( p = 0.585) [ 15 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.